News
-
Zeteo Biomedical said that the company will supply its ZEOx2 nasal delivery system and unit dose packaging for use with a shelf-stable SARS-CoV-2 vaccine in development at the Nanovaccine Institute at Iowa State University. Zeteo is… Read more . . .
-
Milestone Pharmaceuticals has announced the initiation of the RAPID Phase 3 trial of etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). A previous Phase 3 trial, NODE-301, failed to meet its primary… Read more . . .
-
The Drug Delivery to the Lungs (DDL) meeting was due to return to the Edinburgh International Conference Centre December 9-11 this year following the celebration of its 30th anniversary and it’s 15th year bringing hundreds… Read more . . .
-
Revelation Biosciences, which announced in October 2020 that the TGA had approved plans for a Phase 1 study of its REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), said that it has now initiated the trial. According… Read more . . .
-
CDMO Kindeva Drug Delivery announced that it has broken ground on a new 137,500 sq ft headquarters building in Woodbury, MN, USA; the company anticipates that the building will be opened in the latter half… Read more . . .
-
Medigen Vaccine Biologics and BlueWillow Biologics have partnered for development of S-2P-NE-01, an intranasal vaccine against the SARS-CoV-2 virus, the companies said. According to the announcement, the vaccine will include BlueWillow’s NanoVax nasal vaccine adjuvant… Read more . . .
-
TFF Pharmaceuticals and Felix Biotechnology have signed a non-binding letter of intent for a proposed agreement regarding development of an inhaled dry powder bacteriophage for the treatment of lung infections. Felix would need to successfully… Read more . . .
-
Altimmune has signed a manufacturing agreement with Lonza for its AdCOVID intranasal vaccine candidate for the prevention of COVID-19, the companies said. In March 2020, Altimmune announced that it had partnered with the University of… Read more . . .
-
Impel NeuroPharma announced that it has submitted an NDA for its INP104 dihydroergotamine mesylate intranasal (DHE) for the treatment of migraine headaches with or without aura, which is delivered via the company’s Precision Olfactory Delivery… Read more . . .
-
Aptar has announced its acquisition of Cohero Health and all of its assets, including Cohero’s HeroTracker inhaler sensors, BreatheSmart app and platform, and mSpirometer sensors. Cohero Health CEO Joe Condurso will join Aptar Pharma. Since… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA